Last reviewed · How we verify
Pioglitazone 45 mg
At a glance
| Generic name | Pioglitazone 45 mg |
|---|---|
| Also known as | pioglitazone hydrochloride |
| Sponsor | Pennington Biomedical Research Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) (PHASE1, PHASE2)
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes (PHASE3)
- Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (PHASE2)
- Quantifying Hepatic Mitochondrial Fluxes in Humans (PHASE4)
- Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention (PHASE2)
- Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss (PHASE4)
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? (PHASE4)
- Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone 45 mg CI brief — competitive landscape report
- Pioglitazone 45 mg updates RSS · CI watch RSS
- Pennington Biomedical Research Center portfolio CI